Impella RP System
Abiomed, Inc. · Decision date Sep 20, 2017
What did the FDA approve?
FDA approved the Impella RP System under PMA P170011 on September 20, 2017. The approval covers a temporary non-roller type right heart support blood pump indicated for temporary right ventricular support for up to 14 days in patients with a body surface area of 1.5 m2 or greater who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
The applicant is Abiomed, Inc., and the device is classified under product code PYX in the cardiovascular specialty. The source statement reports the approved indication and duration of support but does not include safety or effectiveness data, clinical trial results, or comparative performance information. No supplement type or supplement reason is recorded, so this entry reflects the original PMA approval rather than a change to a previously approved system.
FDA approval order statement
Approval for the Impella RP System. This device is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 20, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170011
- Regulatory pathway
- Premarket approval application
- Applicant
- Abiomed, Inc.
- Product code
- PYX
- Decision code
- APPR
- Decision date
- Sep 20, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Temporary non-roller type right heart support blood pump.
- Applicant
- Abiomed, Inc.
- Product code
- PYX
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170011 received
Application receipt date recorded by FDA.
P170011 · FDA decision
APPR
P170011/S064 · Related supplement
Impella RP Flex with SmartAssist
Timeline entries are records held by MedtechLedger for P170011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Impella RP Flex with SmartAssistP170011/S064 | Abiomed, Inc. | PMA supplement | Oct 26, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abiomed, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 22 Cherry Hill Dr., Danvers, MA, 01923
Sources and methodology
- Original FDA record: P170011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records